Intraductal tubulopapillary neoplasms of the bile ducts: Clinicopathologic, immunohistochemical, and molecular analysis of 20 cases

Anna Melissa Schlitter, Kee Taek Jang, Günter Klöppel, Burcu Saka, Seung Mo Hong, Hyejeong Choi, George Johan Offerhaus, Ralph H. Hruban, Yoh Zen, Björn Konukiewitz, Ivonne Regel, Michael Allgäuer, Serdar Balci, Olca Basturk, Michelle D. Reid, Irene Esposito, Volkan Adsay

Research output: Contribution to journalArticle

Abstract

Intraductal tubulopapillary neoplasm is a well-established entity in the pancreas. A similar, if not identical, tumor occurs also in the biliary tract. We conducted a multicenter study of 20 such lesions, focusing on their clinicopathologic characteristics and molecular profile. Biliary intraductal tubulopapillary neoplasms were seen in patients in their 60s (mean 62 years). The tumors were intrahepatic 70%, extrahepatic 10%, and perihilar 20%; mean tumor size was 6.9 cm. Histologically, all intraductal tubulopapillary neoplasms showed, in addition to their typical tubular pattern, solid areas (70%) or abortive papillae (50%). Necrosis was common (85%), predominantly focal (40%), and with 'comedocarcinoma-like pattern' in 40%. Immunohistochemically, these neoplasms were characterized by the expression of MUC1 (80%) and MUC6 (30%) and by the absence of MUC2 and MUC5AC. Associated invasive carcinomas were present in 16 (80%), mainly conventional tubular adenocarcinoma (50%). The molecular alterations observed included CDKN2A/p16 (intraductal components 44%, invasive 33%) and TP53 (intraductal components 17%, invasive 9%). Mutations in KRAS (intraductal 6%, invasive 0%), PIK3CA (intraductal 6%, invasive 0%), and loss of SMAD4/DPC4 (intraductal 7%, invasive 0%) were rare. No alterations/mutations were identified in IDH1/2, BRAF, GNAS, EGFR, HER2, and β-catenin. Follow-up information was available for 17 patients (85%) with mean follow-up 44 months. Overall combined survival rates showed favorable prognosis: 1 year 100%, 3 years 90%, and 5 years 90%. In conclusion, despite the relatively high incidence of invasive carcinoma (80%), available follow-up suggests that biliary intraductal tubulopapillary neoplasms have an indolent behavior. Molecular analyses highlight the low prevalence of alterations of common oncogenic signaling pathways in intraductal tubulopapillary neoplasm. Further studies using whole-exome sequencing are required to discover yet unknown molecular changes and to understand the carcinogenesis of intraductal tubulopapillary neoplasms.

Original languageEnglish (US)
Pages (from-to)1249-1264
Number of pages16
JournalModern Pathology
Volume28
Issue number9
DOIs
StatePublished - Sep 3 2015

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Intraductal tubulopapillary neoplasms of the bile ducts: Clinicopathologic, immunohistochemical, and molecular analysis of 20 cases'. Together they form a unique fingerprint.

  • Cite this

    Schlitter, A. M., Jang, K. T., Klöppel, G., Saka, B., Hong, S. M., Choi, H., Offerhaus, G. J., Hruban, R. H., Zen, Y., Konukiewitz, B., Regel, I., Allgäuer, M., Balci, S., Basturk, O., Reid, M. D., Esposito, I., & Adsay, V. (2015). Intraductal tubulopapillary neoplasms of the bile ducts: Clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Modern Pathology, 28(9), 1249-1264. https://doi.org/10.1038/modpathol.2015.61